Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26913203 | 0.93 | KDM5B (0.36) | FGFR1DDR2KDM5BMCL1TNKS | |
| SCHEMBL26913083 | 0.92 | KDM5B (0.37) | FGFR1DDR2KDM5BMCL1TNKS | |
| SCHEMBL26912971 | 0.91 | KDM5B (0.36) | FGFR1DDR2KDM5BMCL1TNKS | |
| SCHEMBL30684260 | 0.89 | FGFR1 (0.35) | FGFR1DDR2KDM5BMCL1TNKS | |
| SCHEMBL26913208 | 0.89 | KDM5B (0.37) | FGFR1DDR2KDM5BMCL1RXRA | |
| SCHEMBL26912192 | 0.89 | KDM5B (0.39) | FGFR1DDR2KDM5BMCL1RXRA | |
| SCHEMBL26912674 | 0.89 | KDM5B (0.35) | FGFR1DDR2KDM5BMCL1TNKS | |
| SCHEMBL26912129 | 0.85 | KDM5B (0.41) | FGFR1DDR2KDM5BMCL1RXRA | |
| SCHEMBL30684174 | 0.85 | MCL1 (0.36) | FGFR1DDR2KDM5BMCL1FLT3 | |
| SCHEMBL26913133 | 0.85 | MCL1 (0.36) | FGFR1DDR2KDM5BMCL1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | FGFR1 2285/4885DDR2 2956/4885KDM5B 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.